Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 26.6. At the end of 2024 the company had a P/S ratio of 17.0.